地佐辛联合舒芬太尼治疗癌痛的临床效果  

Clinical Efficacy of Dezocine Combined with Sufentanil on Cancer Pain

作　　者：王艳冰[1] 孟凡颖[1] 李文亮[1] 夏海波[1] 陈雪梅[1] 

机构地区：[1]内蒙古赤峰学院附属医院,024000

出　　处：《实用癌症杂志》2016年第3期480-482,489,共4页The Practical Journal of Cancer

摘　　要：目的探讨地佐辛联合舒芬太尼治疗癌痛的临床效果。方法将80例癌痛患者随机分为3组,Ⅰ组采用0.3 mg/kg地佐辛治疗,Ⅱ组采用2.0μg/kg舒芬太尼治疗,Ⅲ组采用0.3 mg/kg地佐辛+2.0μg/kg舒芬太尼联合治疗。记录所有患者药物治疗前后生命体征的变化,用药后2、4、12、24、48 h的VAS镇痛评分和Ramsay镇静评分,以及用药后不良反应的发生情况。结果 3组患者用药前后生命体征均无明显变化(P>0.05),3组患者的VAS镇痛评分与治疗前比较明显下降(P<0.05),Ⅲ组各时段VAS镇痛评分均明显低于其他2组(P<0.05),且镇静评分及不良反应与其他两组比较无明显差异(P>0.05)。结论地佐辛联合舒芬太尼对癌痛的治疗效果好,且未增加不良反应,可以安全用于晚期癌症患者。Objective To study the clinical efficacy of dezocine combined with sufentanil on cancer pain. Methods 80 cancer patients were randomly divided into 3 groups, group Ⅰ received 0.3 mg/kg dezocine treatment, group Ⅱ received 2.0 μg/ kg sufentanil treatment, group Ⅲ received 0.3 mg/kg ＋ 2.0 μg/kg sufentanil combined with dezocine treatment. Changes of vital signs before and after drug treatment were recorded, VAS pain score and Ramsay sedation scores of patients 2,4,12,24,48 h after medication, and adverse reactions were recorded. Results There showed no significant difference in vital signs before and after treatment of the 3 groups （ P 〉 0.05 ） , VAS pain score of the 3 groups decreased significantly after treatment （ P 〈 0.05 ） , VAS score in each period of group Ⅲ were significantly lower than those of the other 2 groups （P 〈 0.05 ）, and sedation score and adverse reactions compared with the other 2 groups had no significant difference （ P 〉 0.05 ）. Conclusion Dezocine combined with sufentanil for cancer pain is effective without increase of adverse reactions, and it can be safely used in patients with advanced cancer.

关 键 词：地佐辛 舒芬太尼 癌痛 

分 类 号：R730.5[医药卫生—肿瘤]